ReviewBrain research bulletin2010
Diabetic keratopathy and treatment by modulation of the opioid growth factor (OGF)-OGF receptor (OGFr) axis with naltrexone: a review.
Review in Brain research bulletin, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- A systematic review on the impact of diabetes mellitus on the ocular surface.Nutrition & diabetes · 2017Pooled it
- The role of adiponectin and AdipoR1/AKT signaling axis in mediating diabetic corneal epithelial wound healing and sensory nerve regeneration.Eye and vision (London, England) · 2025Article
- Current and Emerging Therapeutic Strategies for the Management of Neurotrophic Keratitis.Drugs · 2025Review
- Topical naltrexone increases aquaporin 5 production in the lacrimal gland and restores tear production in diabetic rats.Experimental biology and medicine (Maywood, N.J.) · 2024Article
- Elevated Opioid Growth Factor Alters the Limbus in Type 1 Diabetic Rats.Journal of diabetes and clinical research · 2023Article
- Comparative Genomics Provides Insights into Adaptive Evolution in Tactile-Foraging Birds.Genes · 2022Article
- Opioids and Ocular Surface Pathology: A Literature Review of New Treatments Horizons.Journal of clinical medicine · 2022Review
- Diabetic Corneal Neuropathy: Pathogenic Mechanisms and Therapeutic Strategies.Frontiers in pharmacology · 2022Review
- Sex differences in the magnitude of diabetic ocular surface complications: Role of serum OGF.Physiology & behavior · 2021Article
- Systemic diseases and the cornea.Experimental eye research · 2021Review
- Novel nanopolymer RNA therapeutics normalize human diabetic corneal wound healing and epithelial stem cells.Nanomedicine : nanotechnology, biology, and medicine · 2021Article
- An Update on Corneal Biomechanics and Architecture in Diabetes.Journal of ophthalmology · 2019Review
- Diabetic complications in the cornea.Vision research · 2017Review
- Selective opioid growth factor receptor antagonists based on a stilbene isostere.Bioorganic & medicinal chemistry · 2017Article
- Determination of Risk Factors and Treatment of Dry Eye Disease in Type 1 Diabetes Before Corneal Complications at Sindh Institute of Ophthalmology And Visual Sciences.The open ophthalmology journal · 2017Article
- Intranasal delivery of nanomicelle curcumin promotes corneal epithelial wound healing in streptozotocin-induced diabetic mice.Scientific reports · 2016Article
- Progress in corneal wound healing.Progress in retinal and eye research · 2015Review
- Aloe vera gel facilitates re-epithelialization of corneal alkali burn in normal and diabetic rats.Clinical ophthalmology (Auckland, N.Z.) · 2015Article
- Wounding the cornea to learn how it heals.Experimental eye research · 2014Review
- Synergistic effect of methionine encephalin (MENK) combined with pidotimod(PTD) on the maturation of murine dendritic cells (DCs).Human vaccines & immunotherapeutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The opioid growth factor (OGF)-OGF receptors (OGFr) axis plays an important role in the homeostasis and re-epithelialization of the mammalian cornea. This tonically active growth regulatory inhibitory pathway is involved in cell replication, and the endogenous neuropeptide OGF targets cyclin-dependent kinase inhibitors, p16 and/or p21. Blockade of OGF-OGFr interfacing by systemic or topical administration of opioid antagonists such as naltrexone (NTX) results in accelerated DNA synthesis, cell replication, and tissue repair. Molecular manipulation of OGFr using sense constructs delayed corneal re-epithelialization, whereas antisense constructs accelerated repair of the corneal surface. Corneal keratopathy, a significant complication of diabetes mellitus, is manifested by delays in corneal re-epithelialization following surgery, injury, or disease. Tissue culture studies have shown that addition of NTX stimulates DNA synthesis and explant outgrowth of rabbit corneal epithelium, whereas OGF depresses DNA synthesis and explant outgrowth in a receptor-mediated manner. NTX accelerated corneal re-epithelialization in organ cultures of human and rabbit cornea. Systemic application of NTX to the abraded corneas of rats, and topical administration of NTX to the injured rabbit ocular surface, increased re-epithelialization. Systemic injections or topical administration of NTX facilitates re-epithelialization of the cornea in diabetic rats. Given the vital role of the corneal epithelium in maintaining vision, the frequency of corneal complications related to diabetes (diabetic keratopathy), and the problems occurring in diabetic individuals postoperatively (e.g., vitrectomy), and that conventional therapies such as artificial tears and bandage contact lenses often fail, topical application of NTX merits clinical consideration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.